Open AccessEstimating the number of symptomatic SARS-CoV-2 infections among vaccinated individuals in the United States—January–July, 2021
Author(s) -
Kiersten J. Kugeler,
John D. Williamson,
Aaron T. Curns,
Jessica M. Healy,
Leisha D. Nolen,
Thomas A. Clark,
Stacey W. Martin,
Marc Fischer
Publication year - 2022
Publication title -
plos one
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.99
H-Index - 332
ISSN - 1932-6203
DOI - 10.1371/journal.pone.0264179
Subject(s) - medicine , vaccination , transmission (telecommunications) , covid-19 , population , vaccine efficacy , food and drug administration , environmental health , public health , virology , immunology , disease , infectious disease (medical specialty) , electrical engineering , nursing , engineering
As of March 2021, three COVID-19 vaccines had been authorized by the U.S. Food and Drug Administration (FDA) for use in the United States. Each has substantial efficacy in preventing COVID-19. However, as efficacy from trials was 156 million fully vaccinated people. With high SARS-CoV-2 transmission and increasing numbers of people vaccinated in the United States, vaccine breakthrough infections will continue to accumulate. Understanding expectations regarding number of vaccine breakthrough infections enables accurate public health messaging to help ensure that the occurrence of such cases does not negatively affect vaccine perceptions, confidence, and uptake.